Viral hemorrhagic fevers are a group of serious illnesses caused by viruses. They often start suddenly with fever, headache, and muscle aches. They can also cause bleeding problems. These fevers can affect the kidneys, leading to kidney failure. Doctors call this Hemorrhagic Fever with Renal Syndrome.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Viral hemorrhagic fevers (VHFs) are a group of infections caused by several unrelated families of viruses that share a common pattern: they affect many organs at once and damage the small blood vessels, which can make the body leak fluid, struggle to keep up blood pressure and, in some cases, bleed. The group includes Ebola and Marburg disease, Lassa fever, yellow fever, severe dengue, Crimean-Congo hemorrhagic fever and the hantavirus illnesses. VHF is an umbrella term, not a single disease, and the illnesses in it range from mild to among the most dangerous infections known. About 80% of people infected with Lassa virus have little or no illness, while Ebola has killed about half of the people it infects in past outbreaks. Despite the name, bleeding is not the main feature for most people and, when it happens, tends to come later. Illness usually starts suddenly with fever, exhaustion, muscle aches and headache, often followed by vomiting, diarrhea or belly pain.
Each of these viruses lives naturally in an animal or insect, and that host decides where the disease occurs and how people catch it. Lassa fever and hantaviruses spread from rodent urine and droppings, often through contaminated food, household items or tiny particles in the air. Yellow fever and dengue are carried by mosquitoes, and Crimean-Congo hemorrhagic fever by tick bites or contact with infected livestock. Ebola and Marburg viruses likely come from fruit bats and can pass to people through contact with infected wild animals. Some of these viruses, especially Ebola, Marburg and Lassa, can then spread from person to person through direct contact with blood, vomit, stool or other body fluids, or with contaminated needles, bedding and clothing. A person with Ebola is not contagious before symptoms start. Family caregivers, health workers, laboratory staff and people handling the body of someone who died of the disease face the highest risk when protective equipment is not used. For most people in the United States the risk is very low. It rises mainly with travel to or work in areas where a specific virus circulates, particularly during an outbreak, and with close contact with rodents in places where hantaviruses are found.
Early symptoms look much like malaria, typhoid fever, influenza and other common infections, so no clinician can identify a VHF by examination alone. The most important first clue is history: where the person has been in roughly the past three weeks, and whether they had contact with a sick person, a body, wild animals, rodents, mosquitoes, ticks or a laboratory sample. Without a relevant exposure, a VHF is very unlikely. When there is a real concern, the person is cared for in isolation while a blood sample is tested. The main test is RT-PCR (reverse transcription polymerase chain reaction), which detects the virus's genetic material; antibody and antigen tests may also be used. For the most dangerous viruses, testing is done in specially equipped laboratories, and public health officials are notified. Clinicians also keep testing for more common causes such as malaria, because a recent trip does not rule out an ordinary illness and both can occur together.
For most VHFs there is no medicine that targets the virus itself, so treatment centers on early, intensive supportive care in a hospital. This means replacing lost fluids and salts, supporting blood pressure and breathing, managing pain, fever and nausea, and treating complications or other infections such as malaria. Starting this care early improves the chance of survival, which is one reason prompt assessment matters. Ebola disease caused by Ebola virus (the Zaire species) is the exception with approved specific treatments: two antibody infusions, Inmazeb (a combination of three monoclonal antibodies) and Ebanga (ansuvimab, a single monoclonal antibody), which attach to the virus and help stop it from infecting cells. They have not been shown to work against Sudan or Bundibugyo ebolaviruses or Marburg virus. The antiviral ribavirin has been used for Lassa fever, but how well it works remains uncertain, and no drug is approved for that illness. Vaccines exist for only a few of these infections. The yellow fever vaccine is highly effective and a single dose usually protects for life; it is recommended for people living in or traveling to areas where yellow fever occurs. Ebola vaccines (Ervebo, and a two-dose regimen called Zabdeno and Mvabea) are used during outbreaks and for health workers at risk, but they protect only against Ebola virus. For most others, including Lassa, Marburg and Crimean-Congo hemorrhagic fever, prevention depends on avoiding rodents, mosquito and tick bites, and unprotected contact with sick people or bodies.
The course depends heavily on which virus is involved. Many infections, such as most cases of Lassa fever or dengue, pass as a short fever illness. In severe cases, people may become critically ill within days, with low blood pressure, organ failure and sometimes bleeding, and need hospital care for one to several weeks. Lassa fever during pregnancy is particularly dangerous for both the pregnant person and the baby. People with Ebola or other highly contagious infections are cared for in isolation, which can mean limited in-person contact with family during treatment. Recovery is often slow. Fatigue, joint and muscle pain, eye problems and emotional effects can last for months, especially after Ebola. Up to a quarter of people who recover from Lassa fever develop hearing loss, which is often permanent, so a hearing check is worthwhile. Some viruses can stay in protected parts of the body after recovery. Ebola virus has been passed through semen more than a year after recovery, so male survivors are advised to use condoms and have semen testing until it shows the virus is gone, or to follow safer sex practices for 12 months if testing is not available. Survivors whose blood tests negative for the virus do not need to be isolated, although stigma can be a real part of recovery.
Before traveling to an area with a known outbreak or where yellow fever occurs, arrange a travel health visit to discuss vaccines and how to avoid exposure. If you develop a fever or other symptoms such as severe headache, muscle pain, vomiting, diarrhea or unexplained bleeding or bruising within 21 days of being in an outbreak area, or after contact with someone who had a VHF, call a doctor or your local health department right away. Call before you go in, and describe your travel, symptoms and exposures so the clinic can arrange to see you safely. After close contact with rodents in an area where hantaviruses occur, fever with deep muscle aches and worsening shortness of breath needs medical care right away; mention the rodent exposure when you call. If someone with a possible exposure becomes severely ill, with heavy bleeding, trouble breathing, confusion or fainting, call 911 and tell the dispatcher about the travel or exposure.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Viral Hemorrhagic Fevers is like, what's helped you, or ask the community a question.